{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010508","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.461854+00:00","generated_at":"2026-05-16T10:46:08.298890+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin estimates FY2025 revenue ~$3.2B; expects $230-260M ROCTAVIAN asset write-down","bullets":["Preliminary FY2025 total revenue ~$3.2B, with VOXZOGO contributing ~$920M.","ROCTAVIAN asset write-down of ~$230-260M in Q4 2025; $0.60-$0.64 non-GAAP EPS impact.","Excluding write-down, previous FY2025 non-GAAP EPS guidance unchanged.","Approximately 200M weighted-average diluted shares outstanding assumed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010508","json":"https://secwatch.observer/filing/0001193125-26-010508.json","markdown":"https://secwatch.observer/filing/0001193125-26-010508.md","text":"https://secwatch.observer/filing/0001193125-26-010508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/0001193125-26-010508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:46:08.298890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}